Literature DB >> 24924954

[Cutaneous sarcomas: update on selected fibrohistiocytic and myofibroblastic tumors].

B Aigner1, S Ugurel, S Kaddu, J C Becker.   

Abstract

BACKGROUND: Malignant fibrohistiocytic tumors are a heterogeneous group of mesenchymal neoplasms that may occur in the skin and subcutaneous tissues. DIAGNOSIS: Diagnosis of these tumors may be difficult, as they are rare, and a wide morphological diversity of types and subtypes has been described. In this update, relevant aspects of selected entities like dermatofibrosarcoma protuberans, desmoid tumor, atypical fibroxanthoma, pleomorphic dermal sarcoma, and myxofibrosarcoma are discussed according to the WHO classification of 2013. The typical clinical feature of these tumors is their mostly asymptomatic appearance. For diagnosis, the histologic workup is therefore the key feature; herein immunohistochemistry as well as molecular diagnostics become increasingly important. THERAPY: The primary treatment for locally resectable tumors is complete surgical removal; chemotherapy, radiation, and targeted therapies with kinase inhibitors are available for inoperable and metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24924954     DOI: 10.1007/s00105-013-2738-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  21 in total

Review 1.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

2.  Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermato-oncology.

Authors:  Ingo Stoffels; Hannah von der Stück; Christian Boy; Thorsten Pöppel; Nina Körber; Maren Weindorf; Joachim Dissemond; Dirk Schadendorf; Joachim Klode
Journal:  J Dtsch Dermatol Ges       Date:  2011-11-21       Impact factor: 5.584

Review 3.  Atypical fibroxanthoma: a review of the literature.

Authors:  Luciano J Iorizzo; Marc D Brown
Journal:  Dermatol Surg       Date:  2011-01-26       Impact factor: 3.398

4.  Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.

Authors:  M P Simon; F Pedeutour; N Sirvent; J Grosgeorge; F Minoletti; J M Coindre; M J Terrier-Lacombe; N Mandahl; R D Craver; N Blin; G Sozzi; C Turc-Carel; K P O'Brien; D Kedra; I Fransson; C Guilbaud; J P Dumanski
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

Review 5.  Desmoid tumors: clinical features and treatment options for advanced disease.

Authors:  Bernd Kasper; Philipp Ströbel; Peter Hohenberger
Journal:  Oncologist       Date:  2011-04-08

Review 6.  Cutaneous fibrohistiocytic tumours - an update.

Authors:  Bostjan Luzar; Eduardo Calonje
Journal:  Histopathology       Date:  2010-01       Impact factor: 5.087

7.  Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems.

Authors:  Hsuan-Ying Huang; Priti Lal; Jing Qin; Murray F Brennan; Cristina R Antonescu
Journal:  Hum Pathol       Date:  2004-05       Impact factor: 3.466

8.  Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant.

Authors:  T Mentzel; E Calonje; C Wadden; R S Camplejohn; A Beham; M A Smith; C D Fletcher
Journal:  Am J Surg Pathol       Date:  1996-04       Impact factor: 6.394

Review 9.  Cutaneous and subcutaneous fibrohistiocytic tumors of intermediate malignancy: an update.

Authors:  Steven D Billings; Andrew L Folpe
Journal:  Am J Dermatopathol       Date:  2004-04       Impact factor: 1.533

Review 10.  Myxofibrosarcoma of the sinus piriformis: case report and literature review.

Authors:  Zhu Qiubei; Lin Cheng; Xu Yaping; Lin Shunzhang; Fan Jingping
Journal:  World J Surg Oncol       Date:  2012-11-15       Impact factor: 2.754

View more
  1 in total

Review 1.  [Atypical fibroxanthoma of the scalp: overview and recent developments].

Authors:  M Hilgers; R U Wahl; M Megahed
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.